Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Analytical Method Development: Heavy Metals Test Method Development – V 2.0

Posted on By

Analytical Method Development: Heavy Metals Test Method Development – V 2.0

SOP for Development of Heavy Metals Test Method in AMD Laboratory


Department Analytical Method Development
SOP No. SOP/AMD/050/2025
Supersedes SOP/AMD/050/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP defines the procedure for developing, optimizing, and validating analytical methods for the detection and

quantification of heavy metals in Active Pharmaceutical Ingredients (APIs), excipients, and finished pharmaceutical products using techniques such as ICP-MS, AAS, or colorimetric wet chemistry.

2. Scope

This SOP applies to the Analytical Method Development (AMD) department for testing heavy metals including lead, cadmium, arsenic, and mercury in raw materials and formulations, in accordance with pharmacopeial (USP <232>, <233>, IP) and ICH Q3D Elemental Impurities guidelines.

3. Responsibilities

  • Analytical Scientist: Performs method development, sample digestion, instrumental analysis, and documentation.
  • Reviewer: Verifies data accuracy and ensures adherence to specifications.
  • QA: Reviews and approves method validation records and ensures compliance with regulatory standards.
  • Head – AMD: Ensures method robustness, reproducibility, and readiness for regulatory submission.

4. Accountability

The Head of AMD is accountable for ensuring all heavy metals test methods are developed and validated in accordance with ICH Q3D and pharmacopeial requirements and are suitable for use in release and stability testing.

See also  Analytical Method Development: Risk Assessment in Analytical Method Development - V 2.0

5. Procedure

5.1 Method Selection

  1. Select appropriate technique based on required sensitivity and matrix:
    • ICP-MS (Inductively Coupled Plasma–Mass Spectrometry) – preferred for multi-elemental trace analysis
    • AAS (Atomic Absorption Spectrophotometry) – suitable for single-element analysis
    • Colorimetric Wet Chemistry (USP <231>) – legacy method, limited use
  2. Define target elements and permitted daily exposure (PDE) limits per ICH Q3D.
  3. Record rationale in Annexure-1: Method Development Justification Sheet.

5.2 Sample Preparation and Digestion

  1. Weigh 100–500 mg of sample into a digestion vessel.
  2. Add nitric acid (65%) or HNO3/H2O2 mixture.
  3. Digest using:
    • Microwave digestion (preferred)
    • Hot plate digestion (for simple matrices)
  4. Cool and dilute to volume with Type I water.
  5. Filter through 0.45 µm membrane if necessary.
  6. Document process in Annexure-2: Sample Digestion Log.

5.3 Instrument Calibration and Setup

  1. Prepare calibration standards for each element using traceable certified reference standards.
  2. Run blank, standards, and system suitability (e.g., recovery from spike).
  3. Verify R² ≥ 0.999 for linearity.
  4. Perform instrument tuning and record performance in Annexure-3: Instrument Calibration Sheet.

5.4 Method Execution

  1. Inject digested samples into ICP-MS/AAS and quantify against calibration curve.
  2. For wet chemistry, compare sample color to standard lead/cadmium solution after hydrogen sulfide treatment.
  3. Ensure analytical run includes:
    • Blank
    • Spiked recovery sample
    • Matrix-matched standard
  4. Calculate elemental concentration (µg/g or ppm).
  5. Document raw data and final results in Annexure-4: Heavy Metal Result Sheet.

5.5 Method Optimization

  1. Optimize:
    • Digestion parameters (acid volume, temperature, duration)
    • Instrument parameters (RF power, nebulizer gas flow, etc.)
    • Matrix-matching of standards and samples
  2. Perform trial runs to assess recovery and reproducibility.
  3. Log optimization trials in Annexure-5: Optimization and Feasibility Record.

5.6 Method Validation

  1. Validate per ICH Q2(R1) and USP <233>:
  2. Specificity: Absence of interference in blank and placebo matrices.
  3. Accuracy: Spike recovery 80–120% of known additions.
  4. Precision: RSD ≤ 15% for 6 replicates.
  5. LOD/LOQ: Based on standard deviation of blank (if applicable).
  6. Linearity: 5 concentration levels; R² ≥ 0.999.
  7. Robustness: Evaluate with slight changes in digestion conditions and instrument settings.
  8. Summarize validation in Annexure-6: Validation Summary Report.

6. Abbreviations

  • ICP-MS: Inductively Coupled Plasma–Mass Spectrometry
  • AAS: Atomic Absorption Spectrophotometry
  • PDE: Permitted Daily Exposure
  • QA: Quality Assurance
  • AMD: Analytical Method Development

7. Documents

  1. Method Development Justification Sheet – Annexure-1
  2. Sample Digestion Log – Annexure-2
  3. Instrument Calibration Sheet – Annexure-3
  4. Heavy Metal Result Sheet – Annexure-4
  5. Optimization and Feasibility Record – Annexure-5
  6. Validation Summary Report – Annexure-6

8. References

  • ICH Q3D – Guideline for Elemental Impurities
  • USP <232> – Elemental Impurities Limits
  • USP <233> – Elemental Impurities Procedures
  • Ph. Eur. 2.4.8 – Heavy Metals
  • ICH Q2(R1) – Validation of Analytical Procedures

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Method Development Justification Sheet

Sample Elements Targeted Technique Selected Reason Prepared By
API-A Pb, Cd, As, Hg ICP-MS Trace-level detection Sunita Reddy

Annexure-2: Sample Digestion Log

Date Sample Acid Used Digestion Method Analyst
03/05/2025 Excipent-B HNO3/H2O2 Microwave Ajay Mehra

Annexure-3: Instrument Calibration Sheet

Element Concentration Range (ppb) R² Value Status
Lead (Pb) 0–100 0.9996 Pass

Annexure-4: Heavy Metal Result Sheet

Sample Element Observed (µg/g) Limit (µg/g) Status
API-A Cd 0.43 0.5 Pass

Annexure-5: Optimization and Feasibility Record

Parameter Condition Observation Conclusion
Digestion Temp 190°C Complete digestion Accepted

Annexure-6: Validation Summary Report

Parameter Acceptance Criteria Results Status
Precision RSD ≤ 15% 10.2% Pass
Accuracy 80–120% 98.6% Pass

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Incorporated ICH Q3D elements and ICP-MS optimization Regulatory Alignment
See also  Analytical Method Development: Method Lifecycle Management - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Creams: SOP for Conducting Heavy Metal Testing in Creams – V 2.0
Next Post: Biosimilars: SOP for Troubleshooting Transfection Failures – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version